Retinal Biologics Market Growth Guide 2025 – With Forecasts for Strategic Decisions

 Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

 
 What is the forecasted revenue size of the retinal biologics industry by 2029?
 The retinal biologics market size has grown rapidly in recent years. It will grow from $25.17 billion in 2024 to $28.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increased incidence of retinal disorders, aging population, rising awareness and early diagnosis, evolving healthcare infrastructure, and increasing healthcare expenditure
 
 The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $44.51 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding therapeutic applications, personalized medicine, emerging market growth, a strong pipeline of biologics, collaborations and partnerships, government initiatives and support. Major trends in the forecast period include non-invasive delivery methods, real-world evidence utilization, expanded indications, regulatory pathway streamlining, and patient-centric outcomes.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp
 
 Which industry-specific innovations are acting as key drivers for the retinal biologics market?
 The increasing prevalence of diabetic eye disease is expected to propel the growth of the retinal biologics market going forward. Diabetic eye disease is a complication of diabetes that affects the eyes by causing vision loss and blindness in people with diabetes. Retinal biologics hold the potential for more precise and effective treatment options, allowing for earlier intervention and improved outcomes in preventing vision loss associated with diabetic eye disease. For instance, in December 2023, according to the data from the Australian Bureau of Statistics, an Australia-based government agency, in 2022, 5.3% of the Australian population (about 1.3 million people) had diabetes, marking a notable rise from 3.3%. Therefore, the increasing prevalence of diabetic eye disease is driving the growth of the retinal biologics market.
 
 Which segment currently leads the retinal biologics market in terms of revenue share?
 The retinal biologics market covered in this report is segmented –
 
 1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor
 2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications
 3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels
 
 Subsegments:
 1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors
 2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins
 
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report
 
 What future trends will impact the direction of the retinal biologics industry?
 Product innovation is a key trend gaining popularity in the retinal biologics market. Major companies operating in the retinal biologics market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced that the U.S. Food and Drug Administration had accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). Acceptance was based on two Phase III trials that showed early and persistent visual improvement with Vabysmo, achieving the primary endpoint of non-inferiority to aflibercept. This product is the first bispecific antibody approved for the eye to treat neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Further studies showed an absence of blood vessel leakage in the retina in Vabysmo patients compared to aflibercept patients.
 
 Who are the top competitors in the global retinal biologics market?
 Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.
 
 What regional dynamics are shaping the future of the global retinal biologics market?
 North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Retinal Biologics Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11911
 
 Need Customized Data On Retinal Biologics Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company